Edition:
United States

People: Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

60.65USD
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
$60.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
326,364
52-wk High
$84.35
52-wk Low
$47.79

Cline, Darren 

Mr. Darren S. Cline is an Executive Vice President of Commercial of Seattle Genetics, Inc. Mr. Cline has served as our Executive Vice President, Commercial since February 2016. Mr. Cline served as our Senior Vice President, Commercial from February 2015 and prior to that as our Vice President, Marketing, Managed Markets and Reimbursements. Prior to joining Seattle Genetics in December 2010, Mr. Cline served as Vice President, Market Access at InterMune, Inc. (subsequently acquired by Roche Holdings) from October 2009 to July 2010, where he was responsible for managed markets access and coverage strategy for the anticipated launch of pirfenidone. Prior to InterMune, Mr. Cline served as Executive Director of Sales at Alexion Pharmaceuticals, Inc., a publicly traded biotechnology company, from October 2006 to October 2009, where he played an integral role in the successful launch of Soliris® in the United States. Prior to Alexion, Mr. Cline served in various sales, marketing and managed markets leadership positions at Amgen Inc., a publicly traded biotechnology company. Mr. Cline received a B.S. degree in Marketing from San Diego State University and an M.B.A. from Pepperdine University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Clay Siegall

8,616,340

Todd Simpson

3,061,800

Jean Liu

2,399,940

Darren Cline

--

Vaughn Himes

2,760,340

Felix Baker

575,165
As Of  30 Dec 2017